Soleus Capital Management’s ChemoCentryx, Inc. CCXI Stock Holding History

Soleus Capital Management’s Portfolio CCXI Stock Details CCXI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-154,400	Closed	-$3.83M	–	92
2022 Q2	$3.83M	Buy	+154,400	New	+$3.4M	0.6%	48
2022 Q1	–	Sell	-68,320	Closed	-$2.49M	–	83
2021 Q4	$2.49M	Buy	+68,320	New	+$2.4M	0.25%	53

Other funds holding CCXI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

SFM

Soros Fund Management New York $9.12B AUM 30.69% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

Soleus Capital Management's CCXI Position: Q3 2022 in Review

Soleus Capital Management sold out of ChemoCentryx, Inc. (CCXI) in Q3 2022, closing a stake of 154,400 shares — an estimated $3.83M sold.

Soleus Capital Management first reported a position in CCXI in Q4 2021 and held it in 2 quarters. The position peaked at $3.83M in Q2 2022. 217 funds tracked by Wall St. Rank hold CCXI as of Q3 2022.

Soleus Capital Management reported no remaining ChemoCentryx, Inc. position as of Q3 2022 after selling out during the quarter.
Soleus Capital Management sold 154,400 ChemoCentryx, Inc. shares in Q3 2022, an estimated $3.83M.
Soleus Capital Management first reported a position in ChemoCentryx, Inc. in Q4 2021 and held it in 2 quarters.
Soleus Capital Management's ChemoCentryx, Inc. position peaked at $3.83M in Q2 2022.
217 funds tracked by Wall St. Rank held ChemoCentryx, Inc. as of Q3 2022.

Based on Soleus Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.